View source for N-of-1 trials

== N-of-1 trials ==

An '''n-of-1 RCT''' is a personalized trial design where a single participant undergoes multiple treatment and control periods, allowing individualized comparisons of interventions. This design is ideal for personalized medicine, chronic symptom management, or determining the optimal treatment for one person.

=== 1. Define the Research Question ===
* Focus on an individual-specific question.
* '''Example''': Does medication A reduce pain more effectively than medication B for this patient?
* Choose outcomes that are personally meaningful (e.g., pain, sleep quality, blood pressure).

=== 2. Select the Intervention and Comparison ===
* Choose two treatments: active vs. placebo, or two active interventions.
* Ensure both can be administered multiple times safely and ethically.
* '''Example''': Compare two pain medications used in alternating periods.

=== 3. Determine the Trial Structure ===
* Use a '''multiple crossover design''' (e.g., A-B-B-A-B-A).
* Include '''washout periods''' between treatments to prevent carryover effects.
* Each treatment period typically lasts 1–2 weeks.

=== 4. Identify Outcomes and Data Collection Methods ===
* Choose a patient-relevant '''primary outcome''' (e.g., pain level).
* Include '''secondary outcomes''' such as side effects or quality of life.
* Use validated tools (e.g., visual analog scales, sleep diaries) or mobile apps for frequent data collection.

=== 5. Sample Size and Power Considerations ===
* Power is based on the number of treatment cycles within one person—not a population.
* Typically, 6–10 crossover cycles are sufficient for reliable interpretation.

=== 6. Develop a Randomization Plan ===
* Randomly assign the sequence of treatments to avoid order effects.
* Use [[blinding]] when feasible (e.g., matching placebos, blinded medication packaging).
* Maintain blinding for both patient and researcher to reduce bias.

=== 7. Plan for Washout Periods ===
* Allow enough time between treatment phases for drug effects to wear off.
* Washout length depends on drug half-life and expected duration of action.

=== 8. Analyze and Interpret Data ===
* Use '''visual plots''' to display outcome trends across periods.
* Apply '''paired statistical tests''' (e.g., paired t-tests) or '''mixed-effects models''' for within-person comparisons.
* Interpretation focuses on individual-level effects, not generalization.

=== 9. Ethical and Practical Considerations ===
* Obtain [[informed consent]] tailored to the individualized and repeated-treatment nature of the trial.
* Monitor closely for adverse effects and address carryover risks.
* Ensure participant understanding and engagement throughout the trial.

=== Example Workflow ===

'''Research Question:''' Does drug A reduce arthritis pain better than drug B for this patient?

* Trial Duration: 6 weeks  
* Randomized sequence of weekly treatment assignments: A or B  
* Daily pain scores collected via a smartphone app  
* Data visualized and analyzed to determine which drug performs better

== Conclusion ==
N-of-1 trials offer a rigorous, personalized approach to treatment evaluation. They are especially suited for chronic conditions, symptom fluctuations, or when treatment effects vary between individuals. When carefully designed and monitored, they can provide high-quality evidence for individualized decision-making.

----

=== Bibliography ===

# Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The N-of-1 randomized controlled trial: clinical usefulness. ''Annals of Internal Medicine''. 1990;112(4):293–299.
# Nikles J, Mitchell G, Schluter P, et al. Aggregating single-patient (N-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. ''Journal of Clinical Epidemiology''. 2011;64(5):471–480.
# Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. ''Journal of Clinical Epidemiology''. 2010;63(12):1312–1323.
# Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The N-of-1 clinical trial: the ultimate strategy for individualizing medicine? ''Personalized Medicine''. 2011;8(2):161–173.
# Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. ''Milbank Quarterly''. 2008;86(4):533–555.

----
''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''